Investigation of serum levels of orexin-A, transforming growth factor β, and leptin in patients with multiple sclerosis.
Body Mass Index
TGF-β
leptin
multiple sclerosis
orexin-A
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
26
11
2021
received:
23
10
2021
accepted:
29
11
2021
pubmed:
12
12
2021
medline:
19
3
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a chronic inflammatory and autoimmune disease affecting various inflammatory and nutritional parameters. Therefore, this study aimed to investigate the relationship between the Body Mass Index (BMI) of MS patients and the serum levels of leptin, orexin-A, and Transforming Growth Factor β (TGF-β). This cross-sectional study included 25 patients suffering from MS and 40 healthy individuals as the case and control groups, respectively. The serum levels of leptin, orexin-A, and TGF-β were assessed in the participants using the Enzyme-Linked Immunosorbent Assay methods. Moreover, data were analyzed using the descriptive statistical indices, t-test, chi-square test, and linear regression test. According to our results, the participants' mean age was 38.04 ± 7.53 and 40.23 ± 5.88 in the case and control groups, respectively. Also, the groups were not significantly different in gender, age, alcohol consumption, and smoking (p > 0.05). It was found that the mean serum levels of orexin-A and TGF-β were significantly lower in the MS patients compared to the control group, while the mean serum leptin levels were significantly higher (42.8 vs. 18.9 ng/ml, p < 0.001). Moreover, there was no significant relationship between the BMI of the MS patients and their serum levels of orexin-A, TGF-β, and leptin (p > 0.05). In conclusion, we found significantly lower levels of orexin-A and TGF-β and a significantly higher level of leptin in the MS patients compared to the control group. In addition, there was no significant relationship between the BMI and the serum levels of orexin-A, TGF-β, and leptin in MS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple sclerosis (MS) is a chronic inflammatory and autoimmune disease affecting various inflammatory and nutritional parameters. Therefore, this study aimed to investigate the relationship between the Body Mass Index (BMI) of MS patients and the serum levels of leptin, orexin-A, and Transforming Growth Factor β (TGF-β).
METHODS
METHODS
This cross-sectional study included 25 patients suffering from MS and 40 healthy individuals as the case and control groups, respectively. The serum levels of leptin, orexin-A, and TGF-β were assessed in the participants using the Enzyme-Linked Immunosorbent Assay methods. Moreover, data were analyzed using the descriptive statistical indices, t-test, chi-square test, and linear regression test.
RESULTS
RESULTS
According to our results, the participants' mean age was 38.04 ± 7.53 and 40.23 ± 5.88 in the case and control groups, respectively. Also, the groups were not significantly different in gender, age, alcohol consumption, and smoking (p > 0.05). It was found that the mean serum levels of orexin-A and TGF-β were significantly lower in the MS patients compared to the control group, while the mean serum leptin levels were significantly higher (42.8 vs. 18.9 ng/ml, p < 0.001). Moreover, there was no significant relationship between the BMI of the MS patients and their serum levels of orexin-A, TGF-β, and leptin (p > 0.05).
CONCLUSIONS
CONCLUSIONS
In conclusion, we found significantly lower levels of orexin-A and TGF-β and a significantly higher level of leptin in the MS patients compared to the control group. In addition, there was no significant relationship between the BMI and the serum levels of orexin-A, TGF-β, and leptin in MS patients.
Identifiants
pubmed: 34894407
doi: 10.1002/jcla.24170
pmc: PMC8761413
doi:
Substances chimiques
LEP protein, human
0
Leptin
0
Lipids
0
Orexins
0
Transforming Growth Factor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24170Subventions
Organisme : Tabriz University of Medical Sciences (ID.: IR T.B.Z.M.E.D.REC.1398.527)
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Front Endocrinol (Lausanne). 2019 Oct 22;10:709
pubmed: 31695678
Psychoneuroendocrinology. 2019 May;103:306-315
pubmed: 30776574
Neurol Clin. 2018 Feb;36(1):1-11
pubmed: 29157392
Neurol Neurochir Pol. 2012 Jan-Feb;46(1):22-8
pubmed: 22426759
Nutrients. 2019 Feb 18;11(2):
pubmed: 30781687
Curr Protein Pept Sci. 2018;19(12):1180-1188
pubmed: 29189146
Front Neurosci. 2020 Aug 28;14:863
pubmed: 32982666
J Leukoc Biol. 2019 Sep;106(3):703-716
pubmed: 31087711
Curr Alzheimer Res. 2006 Jul;3(3):191-5
pubmed: 16842094
J Pediatr Endocrinol Metab. 2007 Jul;20(7):817-23
pubmed: 17849744
J Neuroimmunol. 2019 Feb 15;327:15-21
pubmed: 30683426
J Clin Immunol. 2004 May;24(3):287-93
pubmed: 15114059
J Clin Lab Anal. 2022 Jan;36(1):e24170
pubmed: 34894407
Eur J Immunol. 2017 Mar;47(3):446-453
pubmed: 28102541
Clin Neurol Neurosurg. 2021 Jan;200:106377
pubmed: 33246251
Mult Scler. 2020 Sep;26(10):1237-1246
pubmed: 31161863
EBioMedicine. 2019 May;43:392-410
pubmed: 30981648
Mol Nutr Food Res. 2019 Apr 20;:e1801385
pubmed: 31004461
PLoS Med. 2016 Jun 28;13(6):e1002053
pubmed: 27351487
Mult Scler Relat Disord. 2016 Jan;5:77-80
pubmed: 26856948
J Clin Neurosci. 2020 Aug;78:189-193
pubmed: 32331943
Cytokine. 2017 Oct;98:51-58
pubmed: 27916613
PLoS Pathog. 2013;9(10):e1003675
pubmed: 24098124
Mult Scler. 2015 Jun;21(7):858-65
pubmed: 25392327
Neuromolecular Med. 2021 Jun;23(2):225-235
pubmed: 32399804
Nat Rev Neurosci. 2001 Oct;2(10):734-44
pubmed: 11584311
Cell Transplant. 2019 Sep-Oct;28(9-10):1155-1160
pubmed: 31137960
Nutr Neurosci. 2018 Jul;21(6):377-390
pubmed: 28338444